NEW YORK — Baylor Miraca Genetics Laboratories (Baylor Genetics) said on Wednesday that it has signed a sequencing technology transfer agreement with Japanese clinical testing lab SRL to enable SRL to offer genetic testing for precision medicine in the future.
Baylor Genetics is a Houston-based joint venture between Baylor College of Medicine and Tokyo-based HU Group Holdings — formerly known as Miraca Holdings — established in 2014 to offer genetic testing. SRL is a subsidiary of HU Group.
Under the terms of the agreement, Baylor Genetics will transfer its clinical-grade whole-genome and whole-exome sequencing technology to SRL beginning in 2022 and provide related technical support. Financial and other terms were not disclosed.
"I am confident that this collaboration enables SRL to provide optimal clinical sequencing for Japanese patients by applying the world's best technology with Baylor Genetics," Kazuya Omi, R&D executive officer at SRL, said in a statement.